{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:52:18Z","timestamp":1778295138203,"version":"3.51.4"},"reference-count":43,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>(1) Background: In toxicological laboratories, various screening methods can be used to identify compounds involved in intoxication. High-resolution mass spectrometry has been increasingly used in this context for the last years, because of its sensitivity and reliability. Here, we present the development and validation of a screening method that uses liquid chromatography coupled with a high-resolution mass spectrometer. (2) Methods: This method required only 100 \u00b5L of whole blood or plasma sample. Pretreatment consisted of a rapid and simple deproteinisation with methanol\/acetonitrile and zinc sulphate. This new assay was validated according to international guidelines. (3) Results: To perform the method validation, 53 compounds were selected. The selection criteria were as follows: various chemical structures and therapeutic families (&gt;15), large m\/z distribution, positive or negative ionisation mode, and various elution times. The assays showed high selectivity and specificity, with optimal process efficiency. The identification limits, determined using predefined criteria, were established at sub-therapeutic or therapeutic concentrations. Applicability was evaluated using spiked plasma controls and external quality controls. (4) Conclusions: The new method was then successfully applied to routine clinical and forensic samples.<\/jats:p>","DOI":"10.3390\/ph16010076","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T04:08:07Z","timestamp":1672805287000},"page":"76","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development and Validation of a Non-Targeted Screening Method for Most Psychoactive, Analgesic, Anaesthetic, Anti-Diabetic, Anti-Coagulant and Anti-Hypertensive Drugs in Human Whole Blood and Plasma Using High-Resolution Mass Spectrometry"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-8908","authenticated-orcid":false,"given":"Catherine","family":"Feliu","sequence":"first","affiliation":[{"name":"Department of Pharmacology, EA 3801, SFR CAP-Sant\u00e9, Reims University Hospital, 51 Rue Cognacq-Jay, CEDEX, 51095 Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6214-1613","authenticated-orcid":false,"given":"Celine","family":"Konecki","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, EA 3801, SFR CAP-Sant\u00e9, Reims University Hospital, 51 Rue Cognacq-Jay, CEDEX, 51095 Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1032-0879","authenticated-orcid":false,"given":"Yoann","family":"Cazaubon","sequence":"additional","affiliation":[{"name":"Institute Desbrest of Epidemiology and Public Health, INSERM, Montpellier University, Department of Pharmacology, Montpellier University Hospital, Avenue du Doyen Gaston Giraud, 34090 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Binet","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, EA 3801, SFR CAP-Sant\u00e9, Reims University Hospital, 51 Rue Cognacq-Jay, CEDEX, 51095 Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Vautier","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, EA 3801, SFR CAP-Sant\u00e9, Reims University Hospital, 51 Rue Cognacq-Jay, CEDEX, 51095 Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Fouley","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, EA 3801, SFR CAP-Sant\u00e9, Reims University Hospital, 51 Rue Cognacq-Jay, CEDEX, 51095 Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Gozalo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, EA 3801, SFR CAP-Sant\u00e9, Reims University Hospital, 51 Rue Cognacq-Jay, CEDEX, 51095 Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-7889","authenticated-orcid":false,"given":"Zoubir","family":"Djerada","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, EA 3801, SFR CAP-Sant\u00e9, Reims University Hospital, 51 Rue Cognacq-Jay, CEDEX, 51095 Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1515\/CCLM.2004.250","article-title":"Position of Chromatographic Techniques in Screening for Detection of Drugs or Poisons in Clinical and Forensic Toxicology and\/or Doping Control","volume":"42","author":"Maurer","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cca.2014.08.021","article-title":"Drug Confirmation by Mass Spectrometry: Identification Criteria and Complicating Factors","volume":"438","author":"Yuan","year":"2015","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clinbiochem.2005.01.014","article-title":"Multi-Analyte Procedures for Screening for and Quantification of Drugs in Blood, Plasma, or Serum by Liquid Chromatography-Single Stage or Tandem Mass Spectrometry (LC-MS or LC-MS\/MS) Relevant to Clinical and Forensic Toxicology","volume":"38","author":"Maurer","year":"2005","journal-title":"Clin. Biochem."},{"key":"ref_4","first-page":"38","article-title":"Population Pharmacokinetics of Articaine with 1:200,000 Epinephrine during Third Molar Surgery and Simulation of High-Dose Regimens","volume":"114","author":"Cazaubon","year":"2018","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40262-017-0617-2","article-title":"Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia","volume":"57","author":"Djerada","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpba.2013.08.002","article-title":"Validation of a Fast Method for Quantitative Analysis of Elvitegravir, Raltegravir, Maraviroc, Etravirine, Tenofovir, Boceprevir and 10 Other Antiretroviral Agents in Human Plasma Samples with a New UPLC-MS\/MS Technology","volume":"86","author":"Djerada","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.4155\/bio.15.157","article-title":"Validation of a Fast UPLC-MS\/MS Method for Quantitative Analysis of Opioids, Cocaine, Amphetamines (and Their Derivatives) in Human Whole Blood","volume":"7","author":"Feliu","year":"2015","journal-title":"Bioanalysis"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Feliu, C., Peyret, H., Poitevin, G., Cazaubon, Y., Oszust, F., Nguyen, P., Millart, H., and Djerada, Z. (2019). Complementary Role of P2 and Adenosine Receptors in ATP Induced-Anti-Apoptotic Effects Against Hypoxic Injury of HUVECs. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061446"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Feliu, C., Peyret, H., Brassart-Pasco, S., Oszust, F., Poitevin, G., Nguyen, P., Millart, H., and Djerada, Z. (2020). Ticagrelor Prevents Endothelial Cell Apoptosis through the Adenosine Signalling Pathway in the Early Stages of Hypoxia. Biomolecules, 10.","DOI":"10.3390\/biom10050740"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1570-0232(03)00071-0","article-title":"Comparison of a Preliminary Procedure for the General Unknown Screening of Drugs and Toxic Compounds Using a Quadrupole-Linear Ion-Trap Mass Spectrometer with a Liquid Chromatography-Mass Spectrometry Reference Technique","volume":"789","author":"Marquet","year":"2003","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/rcm.1934","article-title":"Development of a Multi-Target Screening Analysis for 301 Drugs Using a QTrap Liquid Chromatography\/Tandem Mass Spectrometry System and Automated Library Searching","volume":"19","author":"Mueller","year":"2005","journal-title":"Rapid Commun. Mass Spectrom. RCM"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1373\/clinchem.2006.067116","article-title":"Screening of Drugs and Toxic Compounds with Liquid Chromatography-Linear Ion Trap Tandem Mass Spectrometry","volume":"52","author":"Sauvage","year":"2006","journal-title":"Clin. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00216-010-3820-7","article-title":"Fast and Simple Procedure for Liquid-Liquid Extraction of 136 Analytes from Different Drug Classes for Development of a Liquid Chromatographic-Tandem Mass Spectrometric Quantification Method in Human Blood Plasma","volume":"397","author":"Remane","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00216-010-3485-2","article-title":"Detection and Identification of 700 Drugs by Multi-Target Screening with a 3200 Q TRAP LC-MS\/MS System and Library Searching","volume":"396","author":"Dresen","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jat\/34.9.571","article-title":"Screening of Xenobiotics by Ultra-Performance Liquid Chromatography-Mass Spectrometry Using in-Source Fragmentation at Increasing Cone Voltages: Library Constitution and an Evaluation of Spectral Stability","volume":"34","author":"Humbert","year":"2010","journal-title":"J. Anal. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/anatox\/35.5.280","article-title":"Drug Screening of Whole Blood by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry","volume":"35","author":"Oiestad","year":"2011","journal-title":"J. Anal. Toxicol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00216-010-4450-9","article-title":"Development and Practical Application of a Library of CID Accurate Mass Spectra of More than 2500 Toxic Compounds for Systematic Toxicological Analysis by LC-QTOF-MS with Data-Dependent Acquisition","volume":"400","author":"Broecker","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00216-012-5889-7","article-title":"Combined Drug Screening and Confirmation by Liquid Chromatography Time-of-Flight Mass Spectrometry with Reverse Database Search","volume":"403","author":"Gergov","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11742","DOI":"10.1021\/ac503144p","article-title":"Liquid Chromatography, in Combination with a Quadrupole Time-of-Flight Instrument (LC QTOF), with Sequential Window Acquisition of All Theoretical Fragment-Ion Spectra (SWATH) Acquisition: Systematic Studies on Its Use for Screenings in Clinical and Forensic Toxicology and Comparison with Information-Dependent Acquisition (IDA)","volume":"86","author":"Roemmelt","year":"2014","journal-title":"Anal. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/jat\/bks061","article-title":"Rapid Screening for 67 Drugs and Metabolites in Serum or Plasma by Accurate-Mass LC-TOF-MS","volume":"36","author":"Marin","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jat\/bks084","article-title":"Validation of LC-TOF-MS Screening for Drugs, Metabolites, and Collateral Compounds in Forensic Toxicology Specimens","volume":"37","author":"Guale","year":"2013","journal-title":"J. Anal. Toxicol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/jssc.201200921","article-title":"Screening for Illicit and Medicinal Drugs in Whole Blood Using Fully Automated SPE and Ultra-High-Performance Liquid Chromatography with TOF-MS with Data-Independent Acquisition","volume":"36","author":"Pedersen","year":"2013","journal-title":"J. Sep. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/FTD.0b013e3181dca295","article-title":"Perspectives of Liquid Chromatography Coupled to Low- and High-Resolution Mass Spectrometry for Screening, Identification, and Quantification of Drugs in Clinical and Forensic Toxicology","volume":"32","author":"Maurer","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clinbiochem.2010.08.018","article-title":"HPLC-High Resolution Mass Spectrometry in Clinical Laboratory?","volume":"44","author":"Jiwan","year":"2011","journal-title":"Clin. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00216-012-5726-z","article-title":"Current Use of High-Resolution Mass Spectrometry in Drug Screening Relevant to Clinical and Forensic Toxicology and Doping Control","volume":"403","author":"Kolmonen","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/15563650.2012.713108","article-title":"Role of Liquid Chromatography-High-Resolution Mass Spectrometry (LC-HR\/MS) in Clinical Toxicology","volume":"50","author":"Wu","year":"2012","journal-title":"Clin. Toxicol. Phila. Pa"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chroma.2012.08.069","article-title":"What Is the Future of (Ultra) High Performance Liquid Chromatography Coupled to Low and High Resolution Mass Spectrometry for Toxicological Drug Screening?","volume":"1292","author":"Maurer","year":"2013","journal-title":"J. Chromatogr. A"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.4155\/bio.14.164","article-title":"Current Position of High-Resolution MS for Drug Quantification in Clinical & Forensic Toxicology","volume":"6","author":"Meyer","year":"2014","journal-title":"Bioanalysis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00204-016-1764-1","article-title":"High-Resolution Mass Spectrometry in Toxicology: Current Status and Future Perspectives","volume":"90","author":"Maurer","year":"2016","journal-title":"Arch. Toxicol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.aca.2015.08.018","article-title":"Orbitrap Technology for Comprehensive Metabolite-Based Liquid Chromatographic-High Resolution-Tandem Mass Spectrometric Urine Drug Screening\u2014Exemplified for Cardiovascular Drugs","volume":"891","author":"Helfer","year":"2015","journal-title":"Anal. Chim. Acta"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.aca.2017.03.002","article-title":"Liquid Chromatography-High Resolution-Tandem Mass Spectrometry Using Orbitrap Technology for Comprehensive Screening to Detect Drugs and Their Metabolites in Blood Plasma","volume":"965","author":"Helfer","year":"2017","journal-title":"Anal. Chim. Acta"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cca.2016.01.017","article-title":"Fully Automated Semi-Quantitative Toxicological Screening in Three Biological Matrices Using Turbulent Flow Chromatography\/High Resolution Mass Spectrometry","volume":"455","author":"Roche","year":"2016","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.aca.2019.02.011","article-title":"Liquid Chromatography-High Resolution Mass Spectrometry for Broad-Spectrum Drug Screening of Dried Blood Spot as Microsampling Procedure","volume":"1063","author":"Joye","year":"2019","journal-title":"Anal. Chim. Acta"},{"key":"ref_34","unstructured":"European Medicines Agency (EMA) (2022, September 15). Guideline on Bioanalytical Method Validation. Available online: http:\/\/www.ema.europa.eu\/docs\/en_gb\/document_library\/scientific_guideline\/2011\/08\/WC500109686.pdf."},{"key":"ref_35","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration (2022, September 15). Bioanalytical Method Validation. Available online: http:\/\/academy.gmp-compliance.org\/guidemgr\/files\/UCM368107.PDF."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.forsciint.2006.05.021","article-title":"Validation of New Methods","volume":"165","author":"Peters","year":"2007","journal-title":"Forensic Sci. Int."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"(2013). Scientific Working Group for Forensic Toxicology Scientific Working Group for Forensic Toxicology (SWGTOX) Standard Practices for Method Validation in Forensic Toxicology. J. Anal. Toxicol., 37, 452\u2013474.","DOI":"10.1093\/jat\/bkt054"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1570-0232(02)00914-5","article-title":"Optimization of Protein Precipitation Based upon Effectiveness of Protein Removal and Ionization Effect in Liquid Chromatography\u2013Tandem Mass Spectrometry","volume":"785","author":"Polson","year":"2003","journal-title":"J. Chromatogr. B"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.talanta.2013.03.048","article-title":"Ion Suppression; a Critical Review on Causes, Evaluation, Prevention and Applications","volume":"115","author":"Furey","year":"2013","journal-title":"Talanta"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13054-020-02915-5","article-title":"Revisited: Therapeutic and Toxic Blood Concentrations of More than 1100 Drugs and Other Xenobiotics","volume":"24","author":"Schulz","year":"2020","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2337\/dc09-1284","article-title":"Novel Assay of Metformin Levels in Patients with Type 2 Diabetes and Varying Levels of Renal Function: Clinical Recommendations","volume":"33","author":"Frid","year":"2010","journal-title":"Diabetes Care"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/1\/76\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:58:25Z","timestamp":1760119105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/1\/76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ph16010076"],"URL":"https:\/\/doi.org\/10.3390\/ph16010076","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]}}}